Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 3/20 | 0.38 |
| ▸ | REN | P00797 | 2/20 | 0.38 |
| ▸ | LTA4H | P09960 | 3/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GLP1R | P43220 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26208260 | 1.00 | CHRM3 (0.45) | CHRM3ACERENLTA4HCHRNB2 | |
| SCHEMBL26205578 | 0.96 | CHRM3 (0.41) | CHRM3ACERENLTA4HRAB9A | |
| SCHEMBL26727407 | 0.96 | CHRM3 (0.41) | CHRM3ACERENLTA4HRAB9A | |
| SCHEMBL26209373 | 0.94 | CHRM3 (0.41) | CHRM3ACERENLTA4HRAB9A | |
| SCHEMBL26208264 | 0.92 | CHRM3 (0.43) | CHRM3ACERENLTA4HCHRNB2 | |
| SCHEMBL26211462 | 0.91 | CHRM3 (0.36) | CHRM3ACEREN | |
| SCHEMBL26999914 | 0.90 | CHRM3 (0.42) | CHRM3ACERENLTA4HLMNA | |
| SCHEMBL26724267 | 0.88 | CHRM3 (0.42) | CHRM3CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL26724256 | 0.88 | CHRM3 (0.42) | CHRM3CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL24763579 | 0.87 | CHRM3 (0.41) | CHRM3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | CHRM3 179/4885ACE 485/4885REN 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.